Ironwood Pharmaceuticals Inc

Ironwood Pharmaceuticals raised its 2026 total revenue guidance to $460-$485 million from a prior range of $450-$475 million, citing continued prescription demand for its sole marketed product Linzess. Ironwood's share of net profit from Linzess sales in the United States surged 72.6% year over year during the first six months of 2026, and management expects mid-single-digit demand growth for the full year. Linzess, developed and commercialized in the United States through an equal profit-and-loss partnership with AbbVie, also generates royalties for Ironwood from Astellas Pharma in Japan and AstraZeneca in China. A recent FDA approval expanding Linzess' use in pediatric patients with functional constipation, where no FDA-approved prescription pediatric therapies previously existed, adds a further growth opportunity ahead of the company's third-quarter results. Earlier this year Ironwood reduced Linzess' list price to support patient access, and management expects lower mandatory government rebates to drive higher net revenues through 2026. The Zacks Consensus Estimate for 2026 earnings per share has risen to $1.10 from $1.04 over the past 60 days.

Ironwood Pharmaceuticals reported adjusted earnings of 31 cents per share for the second quarter of 2026, beating the Zacks Consensus Estimate of 26 cents. Total revenues were $113 million, missing the estimate of $120 million but surging 32.6% year over year. The company raised its full-year 2026 revenue guidance to a range of $460 to $485 million, up from the prior $450 to $475 million, driven by higher demand for Linzess. U.S. sales of Linzess, recorded by partner AbbVie, are now expected to be between $1.15 billion and $1.20 billion, compared with the earlier projection of $1.13 billion to $1.18 billion. Ironwood also lifted its adjusted EBITDA outlook to more than $310 million from more than $300 million.

Ironwood Pharmaceuticals has appointed Dr. Jeffrey Silber as Chief Medical Officer and Head of Research and Drug Development, succeeding Dr. Michael Shetzline who is retiring after a 30-year career. Dr. Silber will oversee Research and Drug Development, Regulatory Affairs, and Medical Affairs, reporting to CEO Tom McCourt, and officially joins on July 20, 2026. The company also announced that its confirmatory Phase 3 STARS-2 trial of Apraglutide in patients with short bowel syndrome with intestinal failure began in June and is now actively recruiting participants. Apraglutide is being advanced as a potential best-in-class therapy based on positive Phase 3 data. Ironwood's stock is currently trading at $4.08, down 3.09%.